Catalyst
Slingshot members are tracking this event:
Synergy Pharma (SGYP) Plans to Submit Supplemental New Drug Application (sNDA) for Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C) in Q1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SGYP |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 27, 2017
Occurred Source:
http://ir.synergypharma.com/press-releases/detail/1839/synergy-pharmaceuticals-submits-supplemental-new-drug
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Snda, Supplemental New Drug Application, Plecanatide, Irritable Bowel Syndrome With Constipation, Ibs-c
